Whitehawk Therapeutics, Inc. (WHWK)
Nasdaq · Healthcare · Biotechnology
$3.700.00%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $211M
- 52-week range
- $1.87 – $5.50
- 52-week change
- +66.67%
- EPS (trailing)
- −$1.14
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $7.1M (−72.50%)
- Net income
- −$20.6M
- Operating margin
- −1601.1%
- Diluted EPS
- −$0.33
- Free cash flow
- −$98.0M
From the company’s annual report on SEC EDGAR.
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Headquarters: Morristown, United States · 32 employees · ir.whitehawktx.com